Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study
Table 2
HBV DNA levels of the pregnant women during pregnancy and postpartum.
Group A (n=264)
Group B (n=136)
Group C (n=251)
P Group B vs. C
baseline
HBV DNA (log10 copies/mL)
3.51±0.58
7.89±0.80
7.73±0.65
0.034
before delivery
HBV DNA (log10 copies/mL)
3.89±0.45
7.75±0.80
3.60±0.36
<0.001
HBV DNA decline ≥2log10 copies/mL from baseline (n, %)
0
0
237 (94.4%)
<0.001
Undetectable HBV DNA
60 (22.7%)
0
21 (8.4%)
7 months postpartum
HBV DNA (log10 copies/mL)
3.85±0.47
7.74±0.89
3.25±0.21
<0.001
HBV DNA decline ≥2 log10 copies/mL from baseline (n, %)
0
0
251 (100%)
<0.001
Undetectable HBV DNA
63 (23.9%)
0
132 (52.6%)
<0.001
1 year postpartum
HBV DNA (log10 copies/mL)
3.83±0.47
7.71±0.80
3.21±0.20
<0.001
HBV DNA decline ≥ 2 log10 copies/mL from baseline (n, %)
0
0
251 (100%)
<0.001
Undetectable HBV DNA
64 (24.2%)
0
151 (60.2%)
<0.001
Values are reported as mean ± standard deviation, compared with t test; or number (percentage), compared with chi-square test, unless otherwise indicated. Undetectable HBV DNA: HBV DNA < 103 copies/mL. n, number of patients.
